etoricoxib sold trade name arcoxia selective inhibitor developed commercialized merck approved countries worldwide except united states food drug administration sent non approvable letter merck required provide additional patented approved medical use etoricoxib indicated symptomatic relief osteoarthritis oa rheumatoid arthritis ra ankylosing spondylitis pain signs inflammation associated acute gouty cochrane review assessed benefits singledose etoricoxib reduction acute postoperative pain singledose oral etoricoxib provides four times pain relief postoperatively placebo equivalent levels adverse etoricoxib given dose mg effective even better analgesics commonly like nsaids inhibitors share adverse effects fixed drug eruption generalised acute generalized exanthematous pustulosis erythema multiforme like drug induced pretibial serious side effects reported besides usual innocuous ones like selective inhibitor coxib etoricoxib selectively inhibits isoform enzyme cyclooxygenase approximately selectivity inhibition reduces generation prostaglandins pgs arachidonic acid among different functions exerted pgs role inflammation cascade highlighted selective inhibitors show less activity compared traditional nonsteroidal antiinflammatory drugs nsaid reduced activity cause reduced gastrointestinal side effects demonstrated several large clinical trials performed different etoricoxibs safety gastrointestinal tract cardiovascular evaluated medal program consisting three clinical trials medal multinational etoricoxib versus diclofenac arthritis longterm study edge etoricoxib versus diclofenac sodium gastrointestinal tolerability effectiveness edge pooled analysis trials shows etoricoxib rates thrombotic cardiovascular events diclofenac including thrombotic events events per patientyears etoricoxib versus events per patientyears diclofenac arterial thrombotic events events per patientyears etoricoxib versus events per patientyears diclofenac risks heart attack stroke death vascular cause per patientyears etoricoxib versus events per patientyears diclofenac rates upper gastrointestinal events ulcer bleeding perforation obstruction favor etoricoxib group events per patientyears etoricoxib versus events per patientyears diclofenac rates complicated upper gastrointestinal events similar two like rofecoxibs vigor trial medal program also criticized time due mercks choice comparator group testimony fda arthritis advisory committee sidney wolfe pointed unlike vigor trial active comparator naproxen three trials medal program used diclofenac active comparator wolfe showed compared etoricoxib naproxen nonselective cox inhibitor etoricoxib significantly increases risks cardiovascular events degree similar rofecoxibnaproxen comparison compared etoricoxib diclofenac inhibits preferentially worse cv safety profile placebo difference statistically significant also noted increase cardiac events heart failure high blood httpsenwikipediaorgwikietoricoxib